Skip to main content
. Author manuscript; available in PMC: 2013 Jul 22.
Published in final edited form as: Life Sci. 2012 Jun 28;92(0):498–505. doi: 10.1016/j.lfs.2012.06.020

Fig. 3.

Fig. 3

The anti-edematous effects of JZL184 require CB2 receptors, but CB1 receptors are expendable. Panel A. Rimonabant (SR1) did not block the anti-edematous effects of JZL184. ***p<0.001 versus VEH/VEH. Panel B. SR144528 (SR2) blocked the anti-edematous effects of JZL184. ***p<0.001 versus VEH/VEH; ## p<0.05 versus VEH/JZL184. Panel C. The anti-edematous effects of JZL184 occur in CB1 (−/−) mice. **p<0.01, ***p<0.001 versus (+/+)/VEH. Panel D. The anti-edematous effects of JZL184 do not occur in CB2 (−/−) mice (Panel D). ***p<0.001 versus (+/+)/VEH; ### p<0.001 versus (+/+)/JZL184. Values represent the mean (± SEM) difference in paw thickness. N = 5–7/group.